SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after retracting its compounded semaglutide weight-loss pill amid regulatory pressure and legal threats from pharmaceutical giants, leading to community debate where bulls anticipate a rebound from removed legal overhang while bears foresee continued struggles due to perceived leadership failures.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending with its community actively discussing its multichain presence across Solana, BSC, Cronos, and ETH, highlighting a deflationary burn mechanism and positioning it as a unique meme coin poised to bring significant volume to the Cronos chain.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant bullish sentiment and trading interest due to eagerly anticipated Japanese PMDA approval and promising clinical data, including strong pancreatic cancer results. The community is buzzing about its potential as an oncology breakthrough, attracting increased institutional attention.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after strategically acquiring two new sites, effectively doubling its power and data center capacity to meet surging AI/HPC demand. The community is actively discussing its strong partnership with Google and the potential for significant upside as a key infrastructure provider, further bolstered by high short interest.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is seeing intense debate among investors ahead of its upcoming earnings report, with many expecting significant volatility given its AI lending model and sector-wide sentiment. While some anticipate a potential short squeeze fueled by proprietary AI data, others express frustration over management and recent market weakness in the fintech space.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is experiencing sharp volatility amid a broader software sector sell-off, with community discussion polarized between frustration over its market underperformance and strong conviction in its undervalued AI-driven marketing technology and consistent fundamental growth, all while awaiting its upcoming earnings report.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as the FDA has accepted its New Drug Application for CTx-1301, setting a PDUFA date of May 31, 2026, which the community sees as a major de-risking event alongside pending US patent approval. Investors are highly optimistic about the drug's innovative "Precision Timed Release" technology transforming ADHD treatment and driving significant upside for the low-float stock, with many speculating on a potential buyout.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies (PGY) is experiencing heightened community speculation and bullish sentiment heading into its upcoming Q4 earnings report, fueled by a notable short interest and recent strategic agreements. Investors are actively debating the potential for a short squeeze and a significant re-rating of its AI-driven credit platform amidst perceived undervaluation.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as widespread frustration mounts over technical glitches disrupting its Super Bowl prediction market, intensifying community debate around its strong correlation with Bitcoin's recent volatility and the potential impact on its imminent earnings report.

Eversource Energy engages in the generation, transmission, and distribution of natural gas and electricity. It operates through the following segments: Electric Distribution, Electric Transmission, Natural Gas Distribution, Water Distribution, and Other. The Electric Distribution segment distributes electricity to retail customers. The Electric Transmission segment owns and maintains transmission facilities through CL&P, NSTAR Electric, PSNH, and WMECO. The Natural Gas Distribution segment transmits and distributes natural gas to retail customers. The Water Distribution segment operates five separate regulated water utilities in Connecticut, Massachusetts, and New Hampshire. The company was founded on July 1, 1966, and is headquartered in Springfield, MA.

Eversource Energy

Eversource Energy is trending after Connecticut regulators rejected its Aquarion Water Company sale, prompting investor and community discussion about management's ability to navigate the state's challenging regulatory environment and fund capital plans. This setback has led to a share price decline, despite the company's consistent dividend increases and progress in offshore wind.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside

Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025.

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement 

Shares of Verve Therapeutics, Inc. (VERV) rocketed 75% in pre-market on Tuesday after Eli Lilly and Company (LLY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-verve-therapeutics-advance-one-time-treatments">announced</a> its intent to acquire the company for up to $1.3 billion.Verve is developing gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD), such as low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a), through treatments that may only need to be given once in a lifetime.Under the terms of the deal, Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones. The aggregate value of the deal is approximately $1.3 billion.The upfront purchase price of $10.50 represents a premium of over 67% to Verve’s closing price on Monday.The transaction is expected to close in the third quarter, subject to customary closing conditions.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/VERV">VERV</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1262/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_18_59_AM_png_4e0f45260c.webp" alt="VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1262" height="134"><figcaption>VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the offer seems low.<stembedurl>https://stocktwits.com/XavierXV/message/618132279</stembedurl>Another user believes that the offer is ‘terrible’ for long-term shareholders while being great news for those who bought it recently.<stembedurl>https://stocktwits.com/PensionPulse/message/618129981</stembedurl> Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY</a> stayed unchanged within ‘neutral’ territory, coupled with ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:1268/142;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_21_01_AM_png_80a8da75d9.webp" alt="LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1268" height="142"><figcaption>LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure>Both LLY and VERV stocks are up by about 4% this year.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-expects-tesla-deliveries-to-dip-further-in-2025/chlYvypRRTv">Wells Fargo Expects Tesla Deliveries To Dip Further In 2025, But Retail Says Downward Trend Is Over</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’

Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.

Verve Therapeutics Stock Rockets 76% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B

Equity

Eli Lilly is in late-stage talks to purchase Verve Therapeutics in a transaction that could total $1.3 billion, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/53d021c9-d15f-4471-86ef-e9abfc3ae7db">report</a> by the Financial Times.Verve Therapeutics surged 74.8% after hours to $10.96 following takeover speculation, while Eli Lilly slipped 1.4% to $807.58 during regular trade.The deal features an upfront payment of nearly $1 billion and an additional $300 million, contingent upon clinical results, which would double Verve Therapeutics' current market value to $559 million.Verve is advancing gene-editing treatments for high cholesterol and&nbsp;has disclosed positive Phase 1 findings for its primary drug candidate.&nbsp;The company already has a partnership with Eli Lilly.If completed, the deal would extend Lilly’s focus on early-stage innovation rather than commercial-stage assets — a strategy backed by its financial strength from diabetes and obesity blockbusters Mounjaro and Zepbound, projected to generate over $30 billion this year.Lilly’s potential move comes amid renewed biopharma dealmaking after a subdued period.Recent deals include Sanofi’s $9.5 billion tie-up with Blueprint Medicines and Bristol Myers Squibb’s $11.1 billion collaboration with BioNTech.&nbsp;The Verve deal will reportedly be announced later this week, barring any last-minute changes.On Stocktwits, retail sentiment for Eli Lilly was ‘neutral’ with ‘normal’ message volume, while Verve Therapeutics saw ‘extremely bullish’ sentiment amid ‘extremely high’ message volume.Eli Lilly’s stock has risen 3.8% so far in 2025, while Verve Therapeutics’ stock has gained 4.3%For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks

The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies.

Eli Lilly close to buying gene editing firm Verve for $1.3 bln- FT

Investing.com-- Eli Lilly and Company (NYSE:LLY) is in advanced talks to buy gene editing start-up  Verve Therapeutics  Inc (NASDAQ:VERV), the Financial Times reported on Monday, as the world’s biggest drugmaker seeks to increase its pipeline of experimental drugs. 

What Makes Verve Therapeutics (VERV) a New Buy Stock

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Verve Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

VERV
Verve Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VERV News

VERVVerve Therapeutics Inc